Eversept Partners LP lessened its stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Rating) by 53.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 137,423 shares of the company’s stock after selling 156,680 shares during the period. Eversept Partners LP […]
Tekla Capital Management LLC acquired a new stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Rating) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 35,233 shares of the company’s stock, valued at approximately $681,000. Tekla Capital Management LLC owned approximately 0.07% of Pliant Therapeutics […]
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Rating) – Investment analysts at Cantor Fitzgerald issued their FY2023 earnings per share estimates for shares of Pliant Therapeutics in a research report issued on Monday, May 15th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings per share of ($2.99) for the year. Cantor Fitzgerald […]
Cantor Fitzgerald restated their overweight rating on shares of Pliant Therapeutics (NASDAQ:PLRX – Get Rating) in a research report sent to investors on Monday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Pliant Therapeutics’ FY2023 earnings at ($2.99) EPS. A number of other research firms have also recently issued reports on PLRX. Needham & Company […]
Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Rating) fell 3.5% during trading on Wednesday . The company traded as low as $21.42 and last traded at $21.42. 704,381 shares traded hands during mid-day trading, a decline of 17% from the average session volume of 853,074 shares. The stock had previously closed at $22.20. Analyst […]